Skip to content

Study · In vitro (cells) · mouse · 1991

1 result

The octapeptide corresponding to the region of the highest homology between alpha-interferon and thymosin-alpha 1 effectively competes with both cytokines for common high-affinity receptors on murine thymocytes.

Zav'yalov VP, Navolotskaya EV, Abramov VM, Galaktionov VG, Isaev IS, Kaurov OA, Kozhich AT, Maiorov VA, Prusakov AN, Vasilenko RN

FEBS letters1 Jan 1991Cited by 13 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    On murine thymocytes, thymosin alpha‑1 inhibited the receptor binding of the interferon-alpha 2 (131-138) octapeptide.

    In plain wordsIn mouse thymocytes in the lab, thymosin alpha‑1 blocked the binding of an interferon-derived peptide to its receptors.

    Outcome
    DecreaseInhibition of interferon-alpha 2 (131-138) octapeptide binding to thymocyte receptors
    Study

    mousen: not reported in source

    Murine thymocytes
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Ki
    3 x 10(-7) M
    octapeptide receptor binding, murine thymocytes

    Source sentences

    Summary
    The peptide receptor binding is inhibited by both Hu rIFN-alpha 2 (Ki = 8.6 x 10(-10) M) and thymosin-alpha 1 (TM-alpha 1) (Ki = 3 x 10(-7) M)
    1 context sentence
    Summary · context
    The octapeptide corresponding to human interferon-alpha 2 (Hu IFN-alpha 2) sequence 131-138 has high affinity to murine thymocyte receptors (Kd = 4.2 x 10(-12) M, about 700 receptors per cell).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.